| Literature DB >> 35487272 |
Rina Otsuka1, Fumito Naganuma2, Tadaho Nakamura2, Hideki Miwa3, Rumi Nakayama-Naono4, Takuro Matsuzawa1, Yurika Komatsu1, Yuki Sato1, Yuna Takahashi1, Haruna Tatsuoka-Kitano1, Kazuhiko Yanai1, Takeo Yoshikawa5.
Abstract
Brain histamine acts as a neurotransmitter in the regulation of various brain activities. Previous studies have shown that histamine N-methyltransferase (HNMT), a histamine-metabolizing enzyme, controls brain histamine concentration and brain function. However, the relative contribution of astrocytic or neuronal HNMT to the regulation of the histaminergic system is still inconclusive. Here, we phenotyped astrocytes-specific HNMT knockout (cKO) mice to clarify the involvement of astrocytic HNMT in histamine clearance and brain function. First, we performed histological examinations using HNMT reporter mice and showed a wide distribution of HNMT in the brain and astrocytic HNMT expression. Then, we created cKO mice by Cre-loxP system and confirmed that HNMT expression in cKO primary astrocytes was robustly decreased. Although total HNMT level in the cortex was not substantially different between control and cKO brains, histamine concentration after histamine release was elevated in cKO cortex. In behavioral tests, impaired motor coordination and lower locomotor activity were observed in the cKO mice. However, anxiety-like behaviors, depression-like behaviors, and memory functions were not altered by astrocytic HNMT disruption. Although sleep analysis demonstrated that the quantity of wakefulness and sleep did not change, the increased power density of delta frequency during wakefulness indicated lower cortical activation in cKO mice. These results demonstrate that astrocytic HNMT contributes to histamine clearance after histamine release in the cortex and plays a role in the regulation of motor coordination, locomotor activity, and vigilance state.Entities:
Keywords: Astrocyte; Histamine; Histamine-N-Methyltransferase; Locomotor activity; Motor coordination; Sleep-wake cycle
Mesh:
Substances:
Year: 2022 PMID: 35487272 DOI: 10.1016/j.neuropharm.2022.109065
Source DB: PubMed Journal: Neuropharmacology ISSN: 0028-3908 Impact factor: 5.250